Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis
- PMID: 9932142
- DOI: 10.1007/BF03339885
Calcium, gamma-linolenic acid and eicosapentaenoic acid supplementation in senile osteoporosis
Abstract
Recent animal work suggests that gamma-linolenic acid (GLA) and eicosapentaenoic acid (EPA) enhance calcium absorption, reduce excretion and increase calcium deposition in bone. A pilot study was set up to test the interactions between calcium and GLA + EPA in humans. Sixty-five women (mean age 79.5), taking a background diet low in calcium, were randomly assigned to GLA + EPA or coconut oil placebo capsules; in addition, all received 600 mg/day calcium as the carbonate. Markers of bone formation/degradation and bone mineral density (BMD) were measured at baseline, 6, 12 and 18 months. Twenty-one patients were continued on treatment for a second period of 18 months, after which BMD (36 months) was measured. At 18 months, osteocalcin and deoxypyridinoline levels fell significantly in both groups, indicating a decrease in bone turnover, whereas bone specific alkaline phosphatase rose indicating beneficial effects of calcium given to all the patients. Lumbar and femoral BMD, in contrast, showed different effects in the two groups. Over the first 18 months, lumbar spine density remained the same in the treatment group, but decreased 3.2% in the placebo group. Femoral bone density increased 1.3% in the treatment group, but decreased 2.1% in the placebo group. During the second period of 18 months with all patients now on active treatment, lumbar spine density increased 3.1% in patients who remained on active treatment, and 2.3% in patients who switched from placebo to active treatment; femoral BMD in the latter group showed an increase of 4.7%. This pilot controlled study suggests that GLA and EPA have beneficial effects on bone in this group of elderly patients, and that they are safe to administer for prolonged periods of time.
Similar articles
-
Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.Clin Rheumatol. 2005 Jun;24(3):232-8. doi: 10.1007/s10067-004-1004-6. Epub 2005 Jan 13. Clin Rheumatol. 2005. PMID: 15647969 Clinical Trial.
-
Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study.Clin Endocrinol (Oxf). 1997 Jan;46(1):55-61. doi: 10.1046/j.1365-2265.1997.d01-1750.x. Clin Endocrinol (Oxf). 1997. PMID: 9059558 Clinical Trial.
-
Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.J Bone Miner Res. 2001 Jan;16(1):113-9. doi: 10.1359/jbmr.2001.16.1.113. J Bone Miner Res. 2001. PMID: 11149474 Clinical Trial.
-
Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.J Bone Miner Res. 2002 Oct;17(10):1904-12. doi: 10.1359/jbmr.2002.17.10.1904. J Bone Miner Res. 2002. PMID: 12369794 Clinical Trial.
-
Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.J Bone Miner Res. 1996 Mar;11(3):337-49. doi: 10.1002/jbmr.5650110307. J Bone Miner Res. 1996. PMID: 8852944
Cited by 42 articles
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2020 Feb 29;3(2):CD003177. doi: 10.1002/14651858.CD003177.pub5. Cochrane Database Syst Rev. 2020. PMID: 32114706
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Nov 30;11(11):CD003177. doi: 10.1002/14651858.CD003177.pub4. Cochrane Database Syst Rev. 2018. PMID: 30521670 Free PMC article. Updated.
-
Omega-6 fats for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Nov 29;11(11):CD011094. doi: 10.1002/14651858.CD011094.pub4. Cochrane Database Syst Rev. 2018. PMID: 30488422 Free PMC article.
-
Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD003177. doi: 10.1002/14651858.CD003177.pub3. Cochrane Database Syst Rev. 2018. PMID: 30019766 Free PMC article. Updated. Review.
-
Omega-6 fats for the primary and secondary prevention of cardiovascular disease.Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD011094. doi: 10.1002/14651858.CD011094.pub3. Cochrane Database Syst Rev. 2018. PMID: 30019765 Free PMC article. Updated. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
-
Other Literature Sources
-
Medical